Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The Transcept drug-delivery system enhances the absorption of drug active agents, reduces first-pass drug inactivation by the liver, and decreases the time required for the onset of drug action, potentially to a level approaching that of parenteral administration.
Tesaro is an oncology-focused biopharmaceutical company dedicated to
improving the lives of cancer patients by developing and providing safer
and more effective therapeutics and supportive care products. Since its
founding, Tesaro in-licensed Rolapitant from OPKO Health, as well as
small molecule inhibitors of Anaplastic Lymphoma Kinase from Amgen.
Tesaro plans to develop one or more compounds for oncology indications,
including the treatment of patients with non-small-cell lung cancer.
Sera Prognostics develops simple blood tests that predict preterm birth, preeclampsia and other pregnancy complications. Using these tests, physicians can make early and accurate assessment of pregnancy complication risks so they can effectively manage their patients’ pregnancies.
ReVision Optics develops custom optical solutions dedicated to vision correction. Its first product is the Vue+ inlay, a unique patented refractive surgery solution which improves near vision that has been lost by presbyopia, the eye's natural aging process. Vue+ is approved in Europe, has its CE mark, and ReVision is actively pursuing regulatory approvals and market opportunities worldwide.
RadioRx discovers and develops compounds sourced and adapted from the aerospace industry for treating cancer and other indications.
QuatRx Pharmaceuticals is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas.
PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform that combines PCR with capillary electrophoresis. The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative answers to the clinic. The company’s technology delivers more information to physicians, reduces costs for the lab and enhances patient care by increasing the chances of early disease detection.
On Demand Therapeutics (ODTx) is developing implantable devices to enable on-demand release of drugs to the back of the eye, controlled by the ophthalmologist, leveraging existing equipment and skills. In addition to its own intellectual property, ODTx has acquired rights to the patent portfolio and technical expertise developed by InterWest company MicroCHIPS in the areas of implantable drug delivery and monitoring devices.
Ocera Therapeutics, founded in January 2005, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for gastrointestinal and liver diseases.
NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world. NeuroPace is located in Mountain View, California.